GLP-1 Therapy Beyond Weight Loss: The Longevity Connection

Quick Read Summary. GLP-1 receptor agonists (semaglutide, tirzepatide, and the broader class) entered the public conversation as weight loss medications. The science underneath them is much bigger than that.

GLP-1 (glucagon-like peptide-1) is a natural hormone produced in the gut after eating. It signals the pancreas to release insulin, slows gastric emptying, suppresses glucagon, and activates satiety centers in the brain. Synthetic GLP-1 receptor agonists mimic this hormone with a much longer half-life, allowing once-weekly dosing.

What the SELECT trial actually showed

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity), published in NEJM in November 2023, randomized 17,604 adults aged 45+ with established cardiovascular disease and BMI ≥27 but no diabetes. Over a mean follow-up of 39.8 months on semaglutide 2.4 mg weekly, the primary composite endpoint of cardiovascular death, non-fatal MI, or non-fatal stroke occurred in 6.5% of the semaglutide group versus 8.0% of placebo. A 20% relative reduction (HR 0.80, P<0.001).

Notably: the cardiovascular benefit was largely independent of how much weight was lost. Patients who lost less weight still derived cardiovascular benefit. The benefit was present regardless of baseline HbA1c. Semaglutide is not just a weight loss drug. It is a cardiovascular intervention.

The mechanisms beyond weight loss

• Direct anti-inflammatory effects. GLP-1 receptors are expressed on endothelial cells, vascular smooth muscle, and immune cells. Multiple studies document reduction in inflammatory cytokines (TNF-alpha, IL-6, hs-CRP) on GLP-1 therapy.
• Endothelial function improvement. Brachial artery flow-mediated dilation, a marker of vascular health, improves on GLP-1 therapy.
• Plaque stabilization. Some imaging studies show stabilization or modest regression of coronary plaque.
• Direct cardiomyocyte effects. GLP-1 receptors on heart muscle may contribute to improved diastolic function and reduced heart failure events.
• Renal protection. Reduction in albuminuria and slowing of kidney function decline in patients with diabetes and CKD.

The longevity-medicine framing

In longevity medicine, biological aging is driven by a relatively small set of common mechanisms: chronic low-grade inflammation, insulin resistance and elevated fasting insulin, visceral adiposity, and endothelial dysfunction. GLP-1 therapy affects all four. This is why longevity-medicine practices have increasingly integrated GLP-1 therapy into broader metabolic optimization programs.

Why GLP-1 should not be taken without supervision

• Dose titration matters. Too-rapid titration produces severe GI symptoms.
• Drug-drug interactions and contraindications require screening.
• Some patients develop muscle loss along with fat loss if nutrition and resistance training are not addressed.
• Rebound weight gain after discontinuation is common without a structured maintenance plan.
• Lab monitoring (lipids, HbA1c, kidney function, vitamin and nutritional markers) supports long-term success.

At Arbour Longevity, our medical weight loss program is $299/month and includes GLP-1 therapy, and ongoing provider supervision.

FAQ

Will I regain weight when I stop?

Without a structured maintenance plan, yes, weight regain after GLP-1 discontinuation is common. With a coaching-supported maintenance protocol (nutrition, resistance training, sometimes lower-dose maintenance therapy), durable results are achievable. We have an in house ACE certified health coach.

Will I lose muscle along with fat?

Some patients do. The risk is reduced by incorporating resistance training and adequate protein intake from the start of therapy.

Are compounded GLP-1 medications safe?

Compounded versions vary widely in quality and oversight. At Arbour Longevity, we use FDA-approved formulations through pharmacies with verified sourcing.

References

1. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM.
2. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM.
3. Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for Treatment of Obesity (SURMOUNT-1). NEJM.
4. Drucker DJ. (2024). The GLP-1 journey: from discovery science to therapeutic impact. J Clin Invest.

Educational content. Medical review required. Full long-form draft available in Drive.